Expert In
Bio/Research
The work in my laboratory focuses on the molecular diagnosis of human genetic disease. Our interest is in translating knowledge obtained from basic research studies to the diagnostic arena, and in developing tools and implementing new technology to improve the diagnosis of human genetic disease. ...
Click to Expand >>
Click to Expand >>
Bio/Research
The work in my laboratory focuses on the molecular diagnosis of human genetic disease. Our interest is in translating knowledge obtained from basic research studies to the diagnostic arena, and in developing tools and implementing new technology to improve the diagnosis of human genetic disease. One area of interest is orphan genetic disease. We have utilized techniques such as denaturing high performance liquid chromatography and real-time quantitative PCR, among others, for the detection of mutations and deletions in disease genes implicated in lissencephaly (in collaboration with W.B. Dobyns X-linked myotubular myopathy, pantothenate kinase associated neurodegeneration (formerly Hallervorden-Spatz syndrome), Menkes syndrome, Sotos syndrome and others. Our mutation studies feed into genotype-phenotype correlation studies that are important for better understanding of the molecular basis of these disorders.
Another area of interest is diagnostics related to the field of pharmacogenetics. We are involved in collaborative projects to identify and genotype polymorphisms in several drug-metabolizing enzymes primarily important in the metabolism of anti-cancer agents (PAAR). Our goal is to identify functional polymorphisms that play a role in drug response in patients and to develop testing for such polymorphisms. A group of genes we are working on are those that belong to the UGT gene family, implicated in the metabolism of a variety of compounds ranging from morphine to anticancer-agents such as epirubicin and irinotecan.
We are also interested in gene methylation analysis and its implication in diagnostics. We have developed PCR-based methylation assays for the genetic disorders Prader-Willi syndrome, Angelman syndrome and Fragile X syndrome, which have been implemented clinically. Methylation is an alternative mechanism for gene inactivation and has been documented in several genes in a wide range of cancers. We have performed methylation studies of candidate genes in endometrial carcinoma in an attempt to better understand the pathogenesis of this disorder and for the establishment of genetic markers for diagnostic and prognostic purposes.
Click to Shrink <<
Another area of interest is diagnostics related to the field of pharmacogenetics. We are involved in collaborative projects to identify and genotype polymorphisms in several drug-metabolizing enzymes primarily important in the metabolism of anti-cancer agents (PAAR). Our goal is to identify functional polymorphisms that play a role in drug response in patients and to develop testing for such polymorphisms. A group of genes we are working on are those that belong to the UGT gene family, implicated in the metabolism of a variety of compounds ranging from morphine to anticancer-agents such as epirubicin and irinotecan.
We are also interested in gene methylation analysis and its implication in diagnostics. We have developed PCR-based methylation assays for the genetic disorders Prader-Willi syndrome, Angelman syndrome and Fragile X syndrome, which have been implemented clinically. Methylation is an alternative mechanism for gene inactivation and has been documented in several genes in a wide range of cancers. We have performed methylation studies of candidate genes in endometrial carcinoma in an attempt to better understand the pathogenesis of this disorder and for the establishment of genetic markers for diagnostic and prognostic purposes.
Click to Shrink <<